Enzo Q1 Revenues up 6 Percent, Reaches CDx Deal with Flagship Bio | GenomeWeb

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market yesterday a 6 percent drop in its FY 2014 revenues year over year.

Separately, the firm announced today a deal with Flagship Biosciences to develop companion diagnostics for anatomic pathology applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.